DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. Financials Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Equities
688192
CNE1000055W8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.08 CNY | -3.77% |
|
-6.79% | -16.24% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 14,959 | 16,030 | 19,530 | 16,659 | - | - |
| Enterprise Value (EV) 1 | 14,959 | 16,030 | 19,530 | 16,659 | 16,659 | 16,659 |
| P/E ratio | -19.9 x | -21.6 x | -17.6 x | -16.4 x | -23.8 x | -101 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1,454 x | - | 214 x | 41.5 x | 18.8 x | 8.75 x |
| EV / Revenue | 1,454 x | - | 214 x | 41.5 x | 18.8 x | 8.75 x |
| EV / EBITDA | - | -23.2 x | -18.4 x | -17 x | -26.3 x | -124 x |
| EV / FCF | - | -23.7 x | -19.5 x | -13.5 x | -21 x | 294 x |
| FCF Yield | - | -4.22% | -5.12% | -7.41% | -4.77% | 0.34% |
| Price to Book | 6.07 x | 9.11 x | 23.5 x | -102 x | -19.3 x | -17.9 x |
| Nbr of stocks (in thousands) | 404,183 | 407,160 | 408,151 | 415,653 | - | - |
| Reference price 2 | 37.01 | 39.37 | 47.85 | 40.08 | 40.08 | 40.08 |
| Announcement Date | 2/25/22 | 2/27/23 | 2/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 10.29 | - | 91.29 | 401.3 | 886.3 | 1,903 |
| EBITDA 1 | - | - | -692.4 | -1,060 | -979 | -634.5 | -134 |
| EBIT 1 | - | -669.9 | -735.7 | -1,108 | -1,014 | -699.3 | -164.5 |
| Operating Margin | - | -6,512.85% | - | -1,213.31% | -252.66% | -78.9% | -8.64% |
| Earnings before Tax (EBT) 1 | - | -669.9 | -735.7 | -1,108 | -1,014 | -699.3 | -164.5 |
| Net income 1 | -586.6 | -669.9 | -736 | -1,108 | -1,014 | -699.3 | -164.5 |
| Net margin | - | -6,512.85% | - | -1,213.42% | -252.66% | -78.9% | -8.64% |
| EPS 2 | -1.630 | -1.860 | -1.820 | -2.720 | -2.440 | -1.683 | -0.3950 |
| Free Cash Flow 1 | - | - | -677.2 | -1,000 | -1,235 | -794.8 | 56.73 |
| FCF margin | - | - | - | -1,095.44% | -307.78% | -89.67% | 2.98% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/22/21 | 2/25/22 | 2/27/23 | 2/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -677 | -1,000 | -1,235 | -795 | 56.7 |
| ROE (net income / shareholders' equity) | - | -37.8% | -34.9% | -85% | -426% | - | - |
| ROA (Net income/ Total Assets) | - | - | -30.5% | -62.8% | -73% | -44.6% | -15.1% |
| Assets 1 | - | - | 2,414 | 1,764 | 1,390 | 1,570 | 1,089 |
| Book Value Per Share 2 | - | 6.090 | 4.320 | 2.040 | -0.3900 | -2.080 | -2.240 |
| Cash Flow per Share 2 | - | -1.370 | -1.480 | - | -2.630 | -1.650 | - |
| Capex 1 | - | - | 73.8 | 32.1 | 104 | 117 | 76.5 |
| Capex / Sales | - | - | - | 35.19% | 25.98% | 13.14% | 4.02% |
| Announcement Date | 11/22/21 | 2/25/22 | 2/27/23 | 2/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
40.08
CNY
Average target price
54
CNY
Spread / Average Target
+34.73%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.24% | 2.39B | |
| +10.63% | 115B | |
| +11.75% | 106B | |
| -5.95% | 24.69B | |
| -2.33% | 21.97B | |
| -6.03% | 19.27B | |
| -13.10% | 17.56B | |
| -40.50% | 17.32B | |
| +6.27% | 14.03B | |
| +31.64% | 12.13B |
- Stock Market
- Equities
- 688192 Stock
- Financials Dizal (Jiangsu) Pharmaceutical Co., Ltd.
